Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UCLA researchers develop new PET scanning probe that will allowing monitoring of the immune system

10.06.2008
Probe also will help monitor response to new therapies

Researchers at UCLA's Jonsson Comprehensive Cancer Center have modified a common chemotherapy drug to create a new probe for Positron Emission Tomography (PET), an advance that will allow them to model and measure the immune system in action and monitor response to new therapies.

The discovery, published June 8, 2008 in the early online edition of the journal Nature Medicine, enables scientists to monitor the immune system – at the whole body level in 3D – as it tries to fight some cancers or when it goes awry as it does in autoimmune diseases.

Researchers created the small molecule, called FAC, by slightly altering the molecular structure of one of the most commonly used chemotherapy drugs, gemcitabine. They then added a radiolabel so the cells that take in the probe can be seen during PET scanning.

The probe is based on a fundamental cell biochemical pathway called the DNA Salvage Pathway, which acts as a sort of recycling mechanism that helps with DNA replication and repair. All cells use this biochemical pathway to different degrees. But in lymphocytes and macrophages, the cells of the immune system that initiate immune response, the pathway is activated at very high levels. Because of that, the probe accumulates at high levels in those cells, said Dr. Owen Witte, a researcher at UCLA's Jonsson Cancer Center, a Howard Hughes Medical Institute investigator and senior author of the study.

"This is not a cure or a new treatment, but it will help us to more effectively model and measure the immune system," said Witte, who also serves as director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. "Monitoring immune function using molecular imaging could significantly impact the diagnosis and treatment evaluation of immunological disorders, as well as evaluating whether certain therapies are effective."

Because the probe is labeled with positron emitting particles, cells that take it in glow "hot" under PET scanning, which operates as a molecular camera that enables visualization of biological processes in living organisms. The work, done in animal models, will be further evaluated in subsequent studies. Eventually, Witte said, researchers hope to be able to monitor the immune systems of patients with FAC and other PET probes.

"This measurement is not invasive - it involves a simple injection of the probe," Witte said. "We could do repetitive scans in a single week to monitor immune response."

Using conventional methods, oncologists are forced to wait weeks and often months to determine whether a patient is responding to a therapy. CT and MRI scans are taken before and during treatment and the size of the tumor is measured to determine response – if the tumor is shrinking, the patient is responding. However, patients that don't respond are exposed to potentially toxic therapies for longer than necessary. If the new PET probe can monitor immune response and response to treatment much more quickly – within a week or two – patients would be spared from therapies that aren't working.

One frustrating aspect for many cancer researchers is understanding the role of the immune response in fighting or, in some cases, possibly stimulating tumor growth, said Dr. Kevin Shannon, the Auerback Distinguished Professor of Molecular Oncology at the University of California, San Francisco.

"Dynamic probes like the one developed by UCLA scientists will allow researchers to learn more about the role of the immune response in cancer, how current treatments affect immune cells, and will allow them to quantitatively monitor responses to new modalities such as tumor vaccines," Shannon said. "Probes of this type may also help oncologists more rapidly identify tumors that will respond to certain drugs so treatments can be made more patient-specific."

Witte said the type of multidisciplinary research that led to development of the probe is uniquely suited to UCLA's collaborative strengths. Researchers from the cancer center, the Broad stem cell center and the Crump Institute for Molecular Imaging took part in the study. The PET scanner was invented by UCLA's Michael Phelps, also a co-author on this study.

The work by Witte and his colleagues was prompted by the desire to add to a short list of probes now used in PET scanning and to develop new probes that monitor different molecular functions than the current probes.

"What we wanted to do was to develop new ways to look inside a living organism and gather as much information as we can about the immune system," said Caius Radu, an assistant professor of molecular and medical pharmacology, a Jonsson Cancer Center researcher and the first author of the study. "We wanted to know how cells move from one site in the body to another and find a way to trace them to tumors."

In previous studies, Witte and other UCLA researchers were able to track the immune system as it recognized and responded to cancer. But in those studies, the cells had to be modified with "reporter" genes that sequestered a specifically designed PET probe that allowed scientists to monitor them. The new probe doesn't require modified cells, making it easier and less expensive to use and giving it far broader applications than existing probes. In addition to modeling and measuring the immune system, those applications include stratifying different types of cancers and their response to therapy, defining the level of immune response in both normal and pathological situations and helping to determine whether new drugs prompt an immune response to cancer and other diseases.

"This probe will tell us things about the immune system that existing probes can't," said Radu, who also is a member of the Crump Institute for Molecular Imaging.

Kim Irwin | EurekAlert!
Further information:
http://www.mednet.ucla.edu

More articles from Health and Medicine:

nachricht Infants later diagnosed with autism follow adults’ gaze, but seldom initiate joint attention
24.05.2019 | Schwedischer Forschungsrat - The Swedish Research Council

nachricht When wheels and heads are spinning - DFG research project on motion sickness in automated driving
22.05.2019 | Technische Universität Berlin

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New studies increase confidence in NASA's measure of Earth's temperature

A new assessment of NASA's record of global temperatures revealed that the agency's estimate of Earth's long-term temperature rise in recent decades is accurate to within less than a tenth of a degree Fahrenheit, providing confidence that past and future research is correctly capturing rising surface temperatures.

The most complete assessment ever of statistical uncertainty within the GISS Surface Temperature Analysis (GISTEMP) data product shows that the annual values...

Im Focus: The geometry of an electron determined for the first time

Physicists at the University of Basel are able to show for the first time how a single electron looks in an artificial atom. A newly developed method enables them to show the probability of an electron being present in a space. This allows improved control of electron spins, which could serve as the smallest information unit in a future quantum computer. The experiments were published in Physical Review Letters and the related theory in Physical Review B.

The spin of an electron is a promising candidate for use as the smallest information unit (qubit) of a quantum computer. Controlling and switching this spin or...

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

On Mars, sands shift to a different drum

24.05.2019 | Physics and Astronomy

Piedmont Atlanta first in Georgia to offer new minimally invasive treatment for emphysema

24.05.2019 | Medical Engineering

Chemical juggling with three particles

24.05.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>